focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCavendish Fin Regulatory News (CAV)

Share Price Information for Cavendish Fin (CAV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (9.091%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 11.50
CAV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Statement

29 Sep 2023 07:00

RNS Number : 0410O
Cavendish Financial PLC
29 September 2023
 

29 September 2023

For immediate Release

 

Cavendish Financial plc ("Cavendish" or the "Group")

AGM Trading Statement

Cavendish Financial plc announces the following update ahead of its Annual General Meeting to be held today at 10.00 am:

On 8 September, finnCap Group plc and Cenkos Securities plc completed their merger to create Cavendish Financial plc, a full-service investment bank for ambitious growth companies.

The combined operation consists of just under 200 people operating from its headquarters in One Bartholomew Close, London and its Scottish office in Edinburgh. With 220 quoted clients, the Group has the largest retained client base amongst UK small and midcap investment banks, making it the go-to financial advisory firm for growth and investment companies. In addition to equity capital markets, Cavendish has expertise in M&A, debt advisory and private growth capital. The Group also has a strong global reach through its membership of Oaklins, an international advisory network.

 

Since the merger, the Group has relocated all of the London based Cenkos team to its London headquarters, launched the new operating brand Cavendish, centralised trading onto a single platform and made substantial progress with its IT integration. The integration of the operations team, a key part of delivering the synergies is also nearing completion. The Group will provide a further update on synergy realisation within its inaugural interim results expected to be announced in December.

 

Trading across the City has been quiet during the Summer, but since merger completion the Group has already announced a number of significant transactions which will close in the coming months including acting as sole adviser to Round Hill Royalty Fund Limited on its offer from Concord Cadence Limited, fundraisings for Haydale Graphene PLC and Shield Therapeutics plc and obtaining key regulatory clearances for the equity financing of Allergy Therapeutics by ZQ Capital and Southern Fox.

 

Contacts:

 

Cavendish Financial plc Tel: +44 (0)20 7220 0500

John Farrugia, co-CEO

Julian Morse, co-CEO

 

Grant Thorton UK LLP (Nominated Adviser to Cavendish) Tel: +44 (0)20 7383 5100

Philip Secrett/Samantha Harrison/Samuel Littler

Hudson Sandler (PR adviser to Cavendish)

Dan de Belder Tel: +44 (0) 7977 927142

Rebekah Chapman Tel: +44 (0) 7702 596674

 

 

About Cavendish 

Cavendish is a UK champion for ambitious growth and investment companies. The Group is trusted by public and private companies, operating across industry sectors, to deliver expert services in equity capital markets, M&A, debt advisory and growth capital.

 

Cavendish has offices in the City of London and Edinburgh and has a global reach through its membership of Oaklins. Cavendish Financial plc is quoted on AIM.

 

For more information on Cavendish, please visit www.cavendish.com

 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMUWROROUUKUAR
Date   Source Headline
22nd Apr 202410:00 amRNSDirectors Dealings
8th Apr 20247:01 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSChange of Nominated Adviser
4th Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
19th Mar 20242:26 pmRNSDirectors Dealings and Total Voting Rights
29th Feb 20247:00 amRNSTotal Voting Rights
20th Feb 20247:00 amRNSTotal Voting Rights and Directors Dealings
19th Feb 20247:00 amRNSLaunch of SIP and Co-investment Plan
19th Jan 20247:00 amRNSHolding(s) in Company
20th Dec 202310:19 amRNSIncoming Director Dealing
19th Dec 202311:11 amRNSDirector Dealings
19th Dec 20237:00 amRNSBoard Changes
19th Dec 20237:00 amRNS2024 Interim Results
1st Dec 20237:00 amRNSBlock Admission Return and Total Voting Rights
29th Sep 202310:44 amRNSResult of AGM
29th Sep 20237:00 amRNSAGM Trading Statement
19th Apr 20056:24 pmRNSOffer Update
12th Apr 20053:13 pmRNSAGM Statement
5th Apr 20057:01 amRNSOffer Update/Directorate
2nd Mar 200510:54 amRNSOffer Update
1st Mar 20051:16 pmRNSOffer Update
21st Feb 20057:00 amRNSOffer Update
31st Jan 20059:26 amRNSOffer Document Posted
28th Jan 20055:47 pmRNSDividend Declaration
28th Jan 20054:34 pmRNSOffer by Chrysalis VCT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.